New Drug for Gout

Mountain View Pharmaceuticals & Bio-Technology General (acquired by Savient Pharmaceuticals)

 


Mountain View Pharmaceuticals, and Bio-Technology General (acquired by Savient Pharmaceuticals) with a grant from the BIRD Foundation developed the drug KRYSTEXXA (TM) .The U.S. Food and Drug Administration has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients that are refractory to conventional therapy.